Unlike stimulant-based drugs that make up the bulk of ADHD treatment, including those like Vyvanse and Adderall, atomoxetine is a selective norepinephrine reuptake inhibitor (sNRI). The recall was ...

Opens in a new tab or window Glenmark Pharma recalled 1.48 million bottles of the generic attention deficit-hyperactivity disorder (ADHD) drug atomoxetine due to the presence of a possible carcinogen.

Glenmark Pharmaceuticals, an India-based drug manufacturer has issued a voluntary recall affecting nearly 1.48 million bottles of atomoxetine, a generic medication used to treat ADHD. The recall ...

A Trump executive order forming the commission tasked them with assessing the ‘threat posed by’ ADHD meds. Learn how experts ...

According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to treat ... various strengths are being recalled by Glenmark Pharmaceuticals ...